论文部分内容阅读
目的 :通过观察应用终末期肝病模型 (MEL D)对人工肝治疗终末期肝病预后的预测作用 ,探讨其在临床的应用价值及人工肝支持系统在终末期肝病治疗中的效果。方法 :4 3例患者随机分为治疗组与对照组 ,对其进行 MELD评分 ,并对治疗组进行人工肝后评分 ,观察 3个月后的残废率。结果 :治疗组中 4例治疗前 MELD评分大于 4 0分者 ,3个月死亡率为 10 0 % ,17例治疗前评分30～ 4 0分者 3个月死亡率为 5 3% ;对照组中 6例 MELD评分大于 4 0分者 ,3个月死亡率为10 0 % ,16例治疗前评分 30～ 4 0分者 3个月死亡率为 87% ,与治疗组相比 P<0 .0 5。结论 :MELD评分可以引入临床推广应用 ,人工肝治疗 MEL D评分在 30～ 4 0分的终末期肝病是安全有效的
Objective: To observe the predictive value of end-stage liver disease model (MELD) on the prognosis of patients with end-stage liver disease treated by artificial liver and to explore its clinical value and the effect of artificial liver support system in the treatment of end-stage liver disease. Methods: Forty-three patients were randomly divided into treatment group and control group. MELD score was performed on the patients and the post-operative liver grading was performed on the treatment group. The disability rate after 3 months was observed. Results: In the treatment group, the MELD score of 4 cases before treatment was greater than 40, the mortality rate at 3 months was 10%, and the 3-month mortality rate of 17 cases before treatment was 30-40. The control group The MELD score was higher than 40 in 6 cases and 10 0% in 3 months. The 3-month mortality of 16 patients with pre-treatment score 30-40 was 87%, P <0 compared with that of the treatment group. 0 5. Conclusion: MELD score can be introduced into clinical application. Artificial liver is safe and effective in the treatment of end-stage liver disease with MEL D score of 30 ~ 40